Annual FCF
-$21.85 M
-$5.47 M-33.41%
31 December 2023
Summary:
AIM ImmunoTech annual free cash flow is currently -$21.85 million, with the most recent change of -$5.47 million (-33.41%) on 31 December 2023. During the last 3 years, it has fallen by -$10.89 million (-99.33%). AIM annual FCF is now -1050.11% below its all-time high of -$1.90 million, reached on 31 December 1995.AIM Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$3.27 M
-$31.00 K-0.96%
30 September 2024
Summary:
AIM ImmunoTech quarterly free cash flow is currently -$3.27 million, with the most recent change of -$31.00 thousand (-0.96%) on 30 September 2024. Over the past year, it has increased by +$2.59 million (+44.18%). AIM quarterly FCF is now -492.03% below its all-time high of -$552.00 thousand, reached on 30 June 2003.AIM Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$21.33 M
+$2.59 M+10.82%
30 September 2024
Summary:
AIM ImmunoTech TTM free cash flow is currently -$21.33 million, with the most recent change of +$2.59 million (+10.82%) on 30 September 2024. Over the past year, it has dropped by -$3.19 million (-17.56%). AIM TTM FCF is now -689.85% below its all-time high of -$2.70 million, reached on 31 March 1996.AIM TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AIM Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -33.4% | +44.2% | -17.6% |
| 3 y3 years | -99.3% | +7.8% | -80.2% |
| 5 y5 years | -103.0% | -27.3% | -125.0% |
AIM Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -99.3% | at low | -38.7% | +67.2% | -80.2% | +10.8% |
| 5 y | 5 years | -131.7% | at low | -122.8% | +67.2% | -126.1% | +10.8% |
| alltime | all time | -1050.1% | at low | -492.0% | +67.2% | -689.9% | +10.8% |
AIM ImmunoTech Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.27 M(+1.0%) | -$21.33 M(-10.8%) |
| June 2024 | - | -$3.24 M(-33.5%) | -$23.91 M(+3.8%) |
| Mar 2024 | - | -$4.87 M(-51.1%) | -$23.04 M(+5.4%) |
| Dec 2023 | -$21.85 M(+33.4%) | -$9.96 M(+70.0%) | -$21.85 M(+20.5%) |
| Sept 2023 | - | -$5.86 M(+148.0%) | -$18.14 M(+5.0%) |
| June 2023 | - | -$2.36 M(-35.8%) | -$17.27 M(+0.0%) |
| Mar 2023 | - | -$3.68 M(-41.1%) | -$17.27 M(+5.4%) |
| Dec 2022 | -$16.38 M(+12.2%) | -$6.24 M(+25.2%) | -$16.38 M(+2.1%) |
| Sept 2022 | - | -$4.99 M(+111.7%) | -$16.04 M(+9.9%) |
| June 2022 | - | -$2.36 M(-15.6%) | -$14.59 M(+4.4%) |
| Mar 2022 | - | -$2.79 M(-52.7%) | -$13.98 M(-4.2%) |
| Dec 2021 | -$14.60 M(+33.2%) | -$5.90 M(+66.5%) | -$14.60 M(+23.3%) |
| Sept 2021 | - | -$3.54 M(+103.2%) | -$11.84 M(+4.9%) |
| June 2021 | - | -$1.74 M(-48.9%) | -$11.29 M(+2.5%) |
| Mar 2021 | - | -$3.41 M(+8.6%) | -$11.01 M(+0.4%) |
| Dec 2020 | -$10.96 M(+16.2%) | -$3.14 M(+4.9%) | -$10.96 M(+7.4%) |
| Sept 2020 | - | -$2.99 M(+104.0%) | -$10.21 M(+4.4%) |
| June 2020 | - | -$1.47 M(-56.4%) | -$9.78 M(-12.7%) |
| Mar 2020 | - | -$3.36 M(+41.1%) | -$11.20 M(+18.8%) |
| Dec 2019 | -$9.43 M(-12.4%) | -$2.38 M(-7.1%) | -$9.43 M(-0.5%) |
| Sept 2019 | - | -$2.57 M(-11.1%) | -$9.48 M(-4.7%) |
| June 2019 | - | -$2.89 M(+80.9%) | -$9.95 M(+1.4%) |
| Mar 2019 | - | -$1.59 M(-34.4%) | -$9.81 M(-8.9%) |
| Dec 2018 | -$10.77 M(+34.4%) | -$2.43 M(-19.9%) | -$10.77 M(+18.2%) |
| Sept 2018 | - | -$3.03 M(+10.5%) | -$9.11 M(+13.9%) |
| June 2018 | - | -$2.75 M(+7.4%) | -$7.99 M(+5.8%) |
| Mar 2018 | - | -$2.56 M(+230.7%) | -$7.56 M(-5.6%) |
| Dec 2017 | -$8.01 M(+2.2%) | -$773.00 K(-59.7%) | -$8.01 M(-14.3%) |
| Sept 2017 | - | -$1.92 M(-17.0%) | -$9.35 M(-10.9%) |
| June 2017 | - | -$2.31 M(-23.1%) | -$10.49 M(+7.8%) |
| Mar 2017 | - | -$3.01 M(+42.2%) | -$9.74 M(+24.3%) |
| Dec 2016 | -$7.83 M(-52.6%) | -$2.11 M(-30.9%) | -$7.83 M(-14.0%) |
| Sept 2016 | - | -$3.06 M(+97.0%) | -$9.11 M(-4.7%) |
| June 2016 | - | -$1.55 M(+40.6%) | -$9.56 M(-27.6%) |
| Mar 2016 | - | -$1.10 M(-67.4%) | -$13.20 M(-20.2%) |
| Dec 2015 | -$16.54 M(+12.3%) | -$3.39 M(-3.3%) | -$16.54 M(-4.8%) |
| Sept 2015 | - | -$3.51 M(-32.5%) | -$17.38 M(-2.3%) |
| June 2015 | - | -$5.20 M(+16.8%) | -$17.78 M(+10.2%) |
| Mar 2015 | - | -$4.45 M(+5.4%) | -$16.14 M(+9.6%) |
| Dec 2014 | -$14.73 M(-18.4%) | -$4.22 M(+7.9%) | -$14.73 M(+5.4%) |
| Sept 2014 | - | -$3.91 M(+10.0%) | -$13.97 M(-2.6%) |
| June 2014 | - | -$3.56 M(+17.2%) | -$14.35 M(-3.9%) |
| Mar 2014 | - | -$3.04 M(-12.4%) | -$14.94 M(-17.2%) |
| Dec 2013 | -$18.04 M(-5.6%) | -$3.46 M(-19.3%) | -$18.04 M(-12.3%) |
| Sept 2013 | - | -$4.29 M(+3.6%) | -$20.56 M(-0.5%) |
| June 2013 | - | -$4.14 M(-32.5%) | -$20.67 M(-6.1%) |
| Mar 2013 | - | -$6.14 M(+2.6%) | -$22.03 M(+15.3%) |
| Dec 2012 | -$19.10 M(+57.5%) | -$5.99 M(+36.0%) | -$19.10 M(+10.9%) |
| Sept 2012 | - | -$4.40 M(-19.9%) | -$17.23 M(+10.4%) |
| June 2012 | - | -$5.50 M(+70.9%) | -$15.61 M(+17.0%) |
| Mar 2012 | - | -$3.22 M(-21.9%) | -$13.35 M(+10.0%) |
| Dec 2011 | -$12.13 M(-6.3%) | -$4.12 M(+48.0%) | -$12.13 M(+19.2%) |
| Sept 2011 | - | -$2.78 M(-14.0%) | -$10.18 M(-2.0%) |
| June 2011 | - | -$3.23 M(+61.6%) | -$10.39 M(-2.8%) |
| Mar 2011 | - | -$2.00 M(-7.7%) | -$10.69 M(-17.5%) |
| Dec 2010 | -$12.95 M | -$2.17 M(-27.5%) | -$12.95 M(-5.8%) |
| Sept 2010 | - | -$2.99 M(-15.3%) | -$13.76 M(+2.6%) |
| June 2010 | - | -$3.53 M(-17.2%) | -$13.40 M(+5.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2010 | - | -$4.26 M(+43.6%) | -$12.69 M(+28.5%) |
| Dec 2009 | -$9.87 M(+3.1%) | -$2.97 M(+12.6%) | -$9.87 M(+16.2%) |
| Sept 2009 | - | -$2.64 M(-6.4%) | -$8.49 M(-0.7%) |
| June 2009 | - | -$2.82 M(+94.7%) | -$8.56 M(+4.2%) |
| Mar 2009 | - | -$1.45 M(-9.2%) | -$8.21 M(-14.2%) |
| Dec 2008 | -$9.57 M(-38.4%) | -$1.59 M(-41.0%) | -$9.57 M(-15.9%) |
| Sept 2008 | - | -$2.70 M(+9.1%) | -$11.38 M(-9.3%) |
| June 2008 | - | -$2.47 M(-11.8%) | -$12.55 M(-6.6%) |
| Mar 2008 | - | -$2.81 M(-17.5%) | -$13.43 M(-13.5%) |
| Dec 2007 | -$15.54 M(+2.4%) | -$3.40 M(-12.1%) | -$15.54 M(-6.8%) |
| Sept 2007 | - | -$3.87 M(+15.4%) | -$16.66 M(+5.1%) |
| June 2007 | - | -$3.35 M(-31.7%) | -$15.85 M(-2.8%) |
| Mar 2007 | - | -$4.91 M(+8.4%) | -$16.30 M(+7.4%) |
| Dec 2006 | -$15.17 M(+80.6%) | -$4.53 M(+48.4%) | -$15.17 M(+13.5%) |
| Sept 2006 | - | -$3.05 M(-19.7%) | -$13.36 M(+11.9%) |
| June 2006 | - | -$3.80 M(+0.5%) | -$11.94 M(+18.7%) |
| Mar 2006 | - | -$3.78 M(+39.0%) | -$10.06 M(+19.8%) |
| Dec 2005 | -$8.40 M(+10.6%) | -$2.72 M(+66.7%) | -$8.40 M(+31.9%) |
| Sept 2005 | - | -$1.63 M(-15.2%) | -$6.37 M(-16.5%) |
| June 2005 | - | -$1.93 M(-9.2%) | -$7.63 M(-2.9%) |
| Mar 2005 | - | -$2.12 M(+206.8%) | -$7.85 M(+3.4%) |
| Dec 2004 | -$7.60 M(+5.6%) | -$691.00 K(-76.1%) | -$7.60 M(-10.4%) |
| Sept 2004 | - | -$2.89 M(+34.5%) | -$8.48 M(-5.4%) |
| June 2004 | - | -$2.15 M(+15.3%) | -$8.97 M(+21.7%) |
| Mar 2004 | - | -$1.86 M(+18.3%) | -$7.37 M(+2.4%) |
| Dec 2003 | -$7.20 M(+12.3%) | -$1.58 M(-53.3%) | -$7.20 M(+3.4%) |
| Sept 2003 | - | -$3.37 M(+511.2%) | -$6.96 M(+35.1%) |
| June 2003 | - | -$552.00 K(-67.4%) | -$5.15 M(-12.0%) |
| Mar 2003 | - | -$1.69 M(+26.4%) | -$5.85 M(-8.7%) |
| Dec 2002 | -$6.41 M(-12.0%) | -$1.34 M(-14.6%) | -$6.41 M(-3.1%) |
| Sept 2002 | - | -$1.57 M(+25.2%) | -$6.61 M(-0.2%) |
| June 2002 | - | -$1.25 M(-44.4%) | -$6.62 M(-9.8%) |
| Mar 2002 | - | -$2.25 M(+45.8%) | -$7.34 M(+0.9%) |
| Dec 2001 | -$7.28 M(-11.7%) | -$1.54 M(-2.1%) | -$7.28 M(-2.8%) |
| Sept 2001 | - | -$1.58 M(-20.0%) | -$7.49 M(-4.3%) |
| June 2001 | - | -$1.97 M(-10.0%) | -$7.83 M(-0.1%) |
| Mar 2001 | - | -$2.19 M(+24.7%) | -$7.84 M(-4.9%) |
| Dec 2000 | -$8.24 M(+13.9%) | -$1.76 M(-8.4%) | -$8.25 M(-2.2%) |
| Sept 2000 | - | -$1.92 M(-3.3%) | -$8.43 M(+5.2%) |
| June 2000 | - | -$1.98 M(-23.6%) | -$8.01 M(+2.3%) |
| Mar 2000 | - | -$2.59 M(+33.6%) | -$7.83 M(+8.2%) |
| Dec 1999 | -$7.24 M(+18.7%) | -$1.94 M(+29.4%) | -$7.24 M(-4.7%) |
| Sept 1999 | - | -$1.50 M(-16.7%) | -$7.60 M(-2.6%) |
| June 1999 | - | -$1.80 M(-10.0%) | -$7.80 M(+9.9%) |
| Mar 1999 | - | -$2.00 M(-13.0%) | -$7.10 M(+16.4%) |
| Dec 1998 | -$6.10 M(+32.6%) | -$2.30 M(+35.3%) | -$6.10 M(+15.1%) |
| Sept 1998 | - | -$1.70 M(+54.5%) | -$5.30 M(+17.8%) |
| June 1998 | - | -$1.10 M(+10.0%) | -$4.50 M(0.0%) |
| Mar 1998 | - | -$1.00 M(-33.3%) | -$4.50 M(-2.2%) |
| Dec 1997 | -$4.60 M(-25.8%) | -$1.50 M(+66.7%) | -$4.60 M(+7.0%) |
| Sept 1997 | - | -$900.00 K(-18.2%) | -$4.30 M(-8.5%) |
| June 1997 | - | -$1.10 M(0.0%) | -$4.70 M(+2.2%) |
| Mar 1997 | - | -$1.10 M(-8.3%) | -$4.60 M(-25.8%) |
| Dec 1996 | -$6.20 M(+226.3%) | -$1.20 M(-7.7%) | -$6.20 M(+24.0%) |
| Sept 1996 | - | -$1.30 M(+30.0%) | -$5.00 M(+35.1%) |
| June 1996 | - | -$1.00 M(-63.0%) | -$3.70 M(+37.0%) |
| Mar 1996 | - | -$2.70 M | -$2.70 M |
| Dec 1995 | -$1.90 M | - | - |
FAQ
- What is AIM ImmunoTech annual free cash flow?
- What is the all time high annual FCF for AIM ImmunoTech?
- What is AIM ImmunoTech annual FCF year-on-year change?
- What is AIM ImmunoTech quarterly free cash flow?
- What is the all time high quarterly FCF for AIM ImmunoTech?
- What is AIM ImmunoTech quarterly FCF year-on-year change?
- What is AIM ImmunoTech TTM free cash flow?
- What is the all time high TTM FCF for AIM ImmunoTech?
- What is AIM ImmunoTech TTM FCF year-on-year change?
What is AIM ImmunoTech annual free cash flow?
The current annual FCF of AIM is -$21.85 M
What is the all time high annual FCF for AIM ImmunoTech?
AIM ImmunoTech all-time high annual free cash flow is -$1.90 M
What is AIM ImmunoTech annual FCF year-on-year change?
Over the past year, AIM annual free cash flow has changed by -$5.47 M (-33.41%)
What is AIM ImmunoTech quarterly free cash flow?
The current quarterly FCF of AIM is -$3.27 M
What is the all time high quarterly FCF for AIM ImmunoTech?
AIM ImmunoTech all-time high quarterly free cash flow is -$552.00 K
What is AIM ImmunoTech quarterly FCF year-on-year change?
Over the past year, AIM quarterly free cash flow has changed by +$2.59 M (+44.18%)
What is AIM ImmunoTech TTM free cash flow?
The current TTM FCF of AIM is -$21.33 M
What is the all time high TTM FCF for AIM ImmunoTech?
AIM ImmunoTech all-time high TTM free cash flow is -$2.70 M
What is AIM ImmunoTech TTM FCF year-on-year change?
Over the past year, AIM TTM free cash flow has changed by -$3.19 M (-17.56%)